We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Research interviews
-
1. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
2. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
5. Transmembrane domains and the regulation of trogocytosis in T cells- Dr. Stefano Barbera
-
6. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
-
7. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
8. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
-
10. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
11. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
12. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
13. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
14. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
15. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
16. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
18. Cancer vaccines
- Dr. Elias Sayour
-
19. The regulation of cell therapy
- Prof. Moutih Rafei
-
20. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
21. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
22. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
-
23. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
24. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
25. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
26. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
27. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
29. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
30. MassBank development and future
- Dr. Emma L. Schymanski
-
31. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
32. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
33. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
34. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Clinical interviews
-
35. Predicting asthma exacerbations using machine learning models
- Dr. Nestor Molfino
-
36. Fighting norovirus with a pill: new vaccine shows strong immune response- Dr. Becca Flitter
-
38. PANDAS: a potential link between group A streptococcal infections and neurological disorders
- Prof. P. Patrick Cleary
-
40. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
41. Characterizing barriers to care in migraine
- Prof. Dawn C. Buse
-
42. Monkeypox: etiopathogenesis, prevention, and treatments
- Dr. Dennis Hruby
-
44. Kidney xenotransplantation
- Dr. Douglas J. Anderson
-
45. CAR-T and TCR-T cellular immunotherapies in oncology
- Prof. Sebastian Kobold
-
46. MAPS: the business of medical affairs
- Dr. Danie du Plessis
-
47. Hypertrophic cardiomyopathy: therapies and treatments
- Prof. Srihari Naidu
-
48. Combating the HIV epidemic
- Prof. William Blattner
-
49. Epigenetic pharmaceuticals used in the clinic
- Dr. Thomas Paul
-
50. Precision cancer medicine: development and future
- Prof. Maurie Markman
-
51. Pediatric cancer testing
- Prof. Joshua Schiffman
-
52. Opposition to vaccination: a transatlantic discussion
- Prof. Jonathan Temte
-
53. Elective caesarean sections from an evolutionary perspective
- Prof. Wenda Trevathan
-
54. Antiphospholipid syndrome and Lupus
- Prof. Graham Hughes
-
55. Prescribing medications to children - a GP’s view
- Dr. Amanda Simmons
- Annual Interviews
-
56. Antigen-specific immunotherapy for autoimmune diseases (ASIT)
- Prof. David Cameron Wraith
-
57. Recent key advancements on mechanotransduction in cardiovascular health
- Prof. Martin A. Schwartz
-
58. Recent key advancements in diabetes research
- Prof. Peter Arvan
-
59. Recent developments in pharmacovigilance
- Prof. Saad Shakir
-
60. Recent research in vaccine development
- Prof. Adam Cunningham
-
61. Recent key advancements in research on rare diseases
- Prof. Hugo J. Bellen
-
62. Recent key advancements in research on RNA-based therapies
- Prof. John P. Cooke
-
63. Recent key advancements in research on mental health disorders- Prof. Phillip D. Harvey
Topics Covered
- Antibiotic candidates
- Gram-positive bacterial infections
- Multidrug resistance
- Cross-resistance
Biography
Dr. Ana Martins is a Senior Research Associate in the Biological Research Center Szeged, Hungary. She is interested in studying antibiotic resistance, the evolution of resistance, and discovering new antimicrobials. She has been involved in projects that combine natural product chemistry and bioactivity testing, contributing to published studies on ecdysteroid derivatives and other natural compounds with anticancer and resistance-modulating potential. At BRC, Dr. Martins works in interdisciplinary research, using tools from biophysics, nanobiosensorics, and molecular biology to address issues of microbial resistance and therapeutic modulation.
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Martins, A. (2025, December 31). Anticipating the evolution of resistance to emerging antibiotic candidates [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 2, 2026, from https://doi.org/10.69645/DVUO1682.Export Citation (RIS)
Publication History
- Published on December 31, 2025
Financial Disclosures
- Dr. Ana Martins has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
Anticipating the evolution of resistance to emerging antibiotic candidates
Published on December 31, 2025
8 min
A selection of talks on Pharmaceutical Sciences
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Today, we are
joined by Dr. Ana Martins
from the Biological Research
Center in Szeged, Hungary
to discuss her
recent publication
in Science
Translational Medicine.
In her paper, Ana
demonstrates that
many antibiotic candidates
for gram-positive infections
rapidly induce
multi-drug resistance in
Staphylococcus aureus,
raising concerns
about their long-term efficacy.
Ana, thank you very much
for joining us today.
Dr. Martins: Thank
you for inviting me.
Interviewer: So to start, can
you describe the key findings
from your paper regarding
the evolution of
resistance in
Staphylococcus aureus,
and how these findings challenge
current strategies in
antibiotic development.
Dr. Martins: One of our key
findings is that resistance
can evolve even against
new antibiotic candidates.
So this was true for
antibiotics that share
a target with antibiotics
currently in use,
but also for new molecules with
possible multi-target effects
on the cell envelope,
for example.
We also discovered
that some mutations
conferring resistance
to these new molecules
are already present in
the clinical isolates of
strains resistant to
antibiotics in use.
However, one
surprising finding was
with a repurposed
drug that targets
multiple distinct
cellular functions,
and in this case, resistance
evolution was not observed.
In short, these were
the main results.
Interviewer: The study
provides evidence of
two specific mechanisms
of acquiring resistance.
That is, the selection
of resistant variants